CENTRALIZED PURCHASING IN HEALTH

Detalhes bibliográficos
Autor(a) principal: Aperta, Jorge
Data de Publicação: 2016
Outros Autores: Borges, Andrea, Cadilha, Diana, Dimas, Francisca, Dinis, Cristina, Feio, José, Fonseca, Olímpia, Garcia, Martinha, Marques, Filomena, Ribeiro, João, Rodrigues, Celina, Santos, Cláudia, Teixeira, Carmo, Dimitrovová, Klara
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.25756/rpf.v7i4.97
Resumo: The centralization of purchases has been increasingly a strategic trend, particularly in the health sector. In Portugal, the SPMS, Serviços Partilhados do Ministério da Saúde, E.P.E., was established in 2010 as a central purchasing entity for the health sector. Centralized purchasing can bring advantages, such as increasing the efficiency of the purchasing process, but also disadvantages, such as the possibility of oligopoly by suppliers, generated by imperfect competition, and a diminished response to the most decentralized units. This theme was the subject of a reflection meeting, which aimed to promote a debate on the national framework aspects of this process, challenges of implementation for hospital medicines and suggestions for improvement of this process.The main ideas generated for a successful centralized purchasing indicate that the central purchasing entity should be dynamic and facilitator, should ensuring equity, safety, accessibility and quality of drugs. There should be better planning and rigorous procurement of drugs, and an integrated information system that allows sharing and networking among the central purchasing and the various health institutions, fostering a proximity policy, should be created. Professionals should be trained in the necessary technical procedures for the completion of the acquisition of drugs, and hospital pharmacists should be included as consultants in the development of specific procedures of centralized procurement, according to the hospital’s needs.Finally, this entire process must be followed by constant monitoring through an annual assessment of the economic and financial feasibility. The benefits of the activity performed annually should adequately quantify the quality and efficiency gains that demonstrate the financial impact achieved in scope of the reduction of expense in the National Health Service.
id RCAP_9688b4e8a0eac1f75b10893b50fb1674
oai_identifier_str oai:ojs.farmacoterapia.pt:article/97
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling CENTRALIZED PURCHASING IN HEALTHCOMPRAS CENTRALIZADAS NA SAÚDEThe centralization of purchases has been increasingly a strategic trend, particularly in the health sector. In Portugal, the SPMS, Serviços Partilhados do Ministério da Saúde, E.P.E., was established in 2010 as a central purchasing entity for the health sector. Centralized purchasing can bring advantages, such as increasing the efficiency of the purchasing process, but also disadvantages, such as the possibility of oligopoly by suppliers, generated by imperfect competition, and a diminished response to the most decentralized units. This theme was the subject of a reflection meeting, which aimed to promote a debate on the national framework aspects of this process, challenges of implementation for hospital medicines and suggestions for improvement of this process.The main ideas generated for a successful centralized purchasing indicate that the central purchasing entity should be dynamic and facilitator, should ensuring equity, safety, accessibility and quality of drugs. There should be better planning and rigorous procurement of drugs, and an integrated information system that allows sharing and networking among the central purchasing and the various health institutions, fostering a proximity policy, should be created. Professionals should be trained in the necessary technical procedures for the completion of the acquisition of drugs, and hospital pharmacists should be included as consultants in the development of specific procedures of centralized procurement, according to the hospital’s needs.Finally, this entire process must be followed by constant monitoring through an annual assessment of the economic and financial feasibility. The benefits of the activity performed annually should adequately quantify the quality and efficiency gains that demonstrate the financial impact achieved in scope of the reduction of expense in the National Health Service.A centralização das compras tem vindo a ser cada vez mais uma tendência estratégica, nomeadamente no setor da saúde. Em Portugal, a SPMS, Serviços Partilhados do Ministério da Saúde, E.P.E., foi constituída em 2010 como uma central de compras para o setor da saúde. As compras centralizadas podem trazer vantagens, como o aumento da eficiência do processo de compras, mas também desvantagens, como a possibilidade de oligopólio por parte dos fornecedores, gerada pela concorrência imperfeita, e uma resposta mais demorada às unidades mais descentralizadas.Este tema foi objeto de uma reunião de reflexão, que teve como principal objetivo promover um debate sobre aspetos do enquadramento nacional deste processo, desafios da sua implementação, no que respeita aos medicamentos hospitalares, e sugestões de melhoria deste processo.As principais ideias geradas para o sucesso das compras centralizadas indicam que a central de compras deve ser facilitadora e dinâmica e garantir a equidade, segurança, acessibilidade e qualidade dos medicamentos. Deve existir um melhor planeamento e rigor na aquisição dos medicamentos e deve ser criado um sistema de informação integrado que permita a partilha e a comunicação em rede entre a central de compras e as diversas instituições de saúde, fomentando uma política de proximidade. Os profissionais devem ser formados nos procedimentos técnicos necessários para a realização da aquisição dos medicamentos e os farmacêuticos hospitalares devem ser incluídos como consultores no desenvolvimento de alguns procedimentos de aquisição centralizada, em função das necessidades das unidades hospitalares.Por fim, todo este processo deve ser acompanhado de uma constante monitorização, através de uma avaliação anual sobre a racionalidade económico-financeira e vantagens da atividade desenvolvida na perspetiva dos ganhos de qualidade e eficiência, devidamente quantificados e que demonstrem o impacto financeiro alcançado no âmbito da redução da despesa no Serviço Nacional de Saúde.Formifarma2016-03-12info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.25756/rpf.v7i4.97https://doi.org/10.25756/rpf.v7i4.97Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 7 No 4 (2015): Outubro; 214-220Revista Portuguesa de Farmacoterapia; v. 7 n. 4 (2015): Outubro; 214-2202183-73411647-354Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttp://revista.farmacoterapia.pt/index.php/rpf/article/view/97http://revista.farmacoterapia.pt/index.php/rpf/article/view/97/82Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapiahttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessAperta, JorgeBorges, AndreaCadilha, DianaDimas, FranciscaDinis, CristinaFeio, JoséFonseca, OlímpiaGarcia, MartinhaMarques, FilomenaRibeiro, JoãoRodrigues, CelinaSantos, CláudiaTeixeira, CarmoDimitrovová, Klara2023-09-01T04:33:29Zoai:ojs.farmacoterapia.pt:article/97Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:11:33.930229Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv CENTRALIZED PURCHASING IN HEALTH
COMPRAS CENTRALIZADAS NA SAÚDE
title CENTRALIZED PURCHASING IN HEALTH
spellingShingle CENTRALIZED PURCHASING IN HEALTH
Aperta, Jorge
title_short CENTRALIZED PURCHASING IN HEALTH
title_full CENTRALIZED PURCHASING IN HEALTH
title_fullStr CENTRALIZED PURCHASING IN HEALTH
title_full_unstemmed CENTRALIZED PURCHASING IN HEALTH
title_sort CENTRALIZED PURCHASING IN HEALTH
author Aperta, Jorge
author_facet Aperta, Jorge
Borges, Andrea
Cadilha, Diana
Dimas, Francisca
Dinis, Cristina
Feio, José
Fonseca, Olímpia
Garcia, Martinha
Marques, Filomena
Ribeiro, João
Rodrigues, Celina
Santos, Cláudia
Teixeira, Carmo
Dimitrovová, Klara
author_role author
author2 Borges, Andrea
Cadilha, Diana
Dimas, Francisca
Dinis, Cristina
Feio, José
Fonseca, Olímpia
Garcia, Martinha
Marques, Filomena
Ribeiro, João
Rodrigues, Celina
Santos, Cláudia
Teixeira, Carmo
Dimitrovová, Klara
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Aperta, Jorge
Borges, Andrea
Cadilha, Diana
Dimas, Francisca
Dinis, Cristina
Feio, José
Fonseca, Olímpia
Garcia, Martinha
Marques, Filomena
Ribeiro, João
Rodrigues, Celina
Santos, Cláudia
Teixeira, Carmo
Dimitrovová, Klara
description The centralization of purchases has been increasingly a strategic trend, particularly in the health sector. In Portugal, the SPMS, Serviços Partilhados do Ministério da Saúde, E.P.E., was established in 2010 as a central purchasing entity for the health sector. Centralized purchasing can bring advantages, such as increasing the efficiency of the purchasing process, but also disadvantages, such as the possibility of oligopoly by suppliers, generated by imperfect competition, and a diminished response to the most decentralized units. This theme was the subject of a reflection meeting, which aimed to promote a debate on the national framework aspects of this process, challenges of implementation for hospital medicines and suggestions for improvement of this process.The main ideas generated for a successful centralized purchasing indicate that the central purchasing entity should be dynamic and facilitator, should ensuring equity, safety, accessibility and quality of drugs. There should be better planning and rigorous procurement of drugs, and an integrated information system that allows sharing and networking among the central purchasing and the various health institutions, fostering a proximity policy, should be created. Professionals should be trained in the necessary technical procedures for the completion of the acquisition of drugs, and hospital pharmacists should be included as consultants in the development of specific procedures of centralized procurement, according to the hospital’s needs.Finally, this entire process must be followed by constant monitoring through an annual assessment of the economic and financial feasibility. The benefits of the activity performed annually should adequately quantify the quality and efficiency gains that demonstrate the financial impact achieved in scope of the reduction of expense in the National Health Service.
publishDate 2016
dc.date.none.fl_str_mv 2016-03-12
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.25756/rpf.v7i4.97
https://doi.org/10.25756/rpf.v7i4.97
url https://doi.org/10.25756/rpf.v7i4.97
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv http://revista.farmacoterapia.pt/index.php/rpf/article/view/97
http://revista.farmacoterapia.pt/index.php/rpf/article/view/97/82
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia
http://creativecommons.org/licenses/by-nc-nd/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia
http://creativecommons.org/licenses/by-nc-nd/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Formifarma
publisher.none.fl_str_mv Formifarma
dc.source.none.fl_str_mv Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 7 No 4 (2015): Outubro; 214-220
Revista Portuguesa de Farmacoterapia; v. 7 n. 4 (2015): Outubro; 214-220
2183-7341
1647-354X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799129986160918528